Buspirone as a Candidate Medication for Methamphetamine Abuse

University of Kentucky

Status and phase

Completed

Phase 1

Conditions

Methamphetamine Dependence

Methamphetamine Abuse

Treatments

Drug: Methamphetamine

Drug: Placebo

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT01843205

R21DA035481 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

Methamphetamine use disorders are an unrelenting public health concern. Intensive research efforts have yielded behavioral interventions that reduce methamphetamine use, however, these interventions are not universally effective and treatment effects diminish over time. Development of a pharmacotherapy that enhances the efficacy of these interventions is a priority for the National Institute on Drug Abuse. This study proposes to determine the impact of buspirone maintenance on self-administration of methamphetamine. These preliminary data will be used to support further research developing buspirone as a pharmacotherapy for methamphetamine use disorders. The investigators hypothesize that buspirone will attenuate the reinforcing effects of methamphetamine.

Enrollment

9 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Lifetime methamphetamine use

Exclusion criteria

Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians deem clinically significant
Current or past histories of substance abuse or dependence that are deemed by the study physicians to interfere with study completion
History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation will be excluded from participation
Females not currently using effective birth control
Contraindications to methamphetamine or buspirone